These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 3589695)

  • 21. Double labeling of human leukemic cells using 3H-cytarabine and monoclonal antibody against bromodeoxyuridine.
    Raza A; Preisler HD
    Cancer Treat Rep; 1985 Feb; 69(2):195-8. PubMed ID: 3882228
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Flow cytometric analysis of proliferative characteristics of human leukemic cells in bone marrows in vivo using bromodeoxyuridine (BrdU) and its monoclonal antibody].
    Takeda Y; Kanno M; Nakamura S
    Nihon Rinsho; 1992 Oct; 50(10):2368-73. PubMed ID: 1447806
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Cytosine arabinoside as a polyvalent drug in the treatment of acute non-lymphoid leukemias].
    Sánchez Fayos J
    Sangre (Barc); 1986; 31(5):566-73. PubMed ID: 3810411
    [No Abstract]   [Full Text] [Related]  

  • 24. 5-bromodeoxyuridine (BUdR) quenching of acridine orange fluorescence distinguishes cycling and non-cycling normal and malignant bone marrow cells in vitro.
    Maddox AM; Johnson DA; Keating MJ
    Leuk Res; 1989; 13(9):781-90. PubMed ID: 2796384
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of cytostatic drugs on the kinetics of leukemic blast cells in man.
    Killmann SA
    Schweiz Med Wochenschr; 1974 Feb; 104(8):278-84. PubMed ID: 4814680
    [No Abstract]   [Full Text] [Related]  

  • 26. [Principles of high-dose cytarabinoside treatment].
    Seeber S
    Onkologie; 1985 Feb; 8(1):4-7. PubMed ID: 3885120
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low-dose cytosine arabinoside in the treatment of acute nonlymphoblastic leukemia and myelodysplastic syndromes.
    Hoelzer D; Ganser A; Schneider W; Heimpel H
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):208-11. PubMed ID: 4012339
    [No Abstract]   [Full Text] [Related]  

  • 28. Prolonged unmaintained remission after intensive consolidation therapy in adult acute nonlymphocytic leukemia.
    Cassileth PA; Begg CB; Silber R; Spiers A; Burkart PT; Scharfman W; Knospe WH; Bennett JM; Mazza JJ; Oken MM
    Cancer Treat Rep; 1987 Feb; 71(2):137-40. PubMed ID: 3802110
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Strategy of chemotherapy of a patient with acute leukemia based on the mechanism of action of drugs].
    Uchida M; Ueda T; Nakamura T
    Rinsho Ketsueki; 1986 Aug; 27(8):1445-53. PubMed ID: 3795516
    [No Abstract]   [Full Text] [Related]  

  • 30. Low-dose cytarabine: chromosomal findings suggesting its cytostatic as well as differentiating effect.
    Hossfeld DK; Weh HJ; Kleeberg UR
    Leuk Res; 1985; 9(2):329-30. PubMed ID: 3990338
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multiparameter assessment of the cell cycle effects of bioactive and cytotoxic agents.
    Preisler HD; Gopal V; Banavali SD; Finke D; Bokari SA
    Cancer Res; 1992 Aug; 52(15):4090-5. PubMed ID: 1638520
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cell cycle kinetics in childhood acute leukemia studied with in vitro bromodeoxyuridine labeling, Ki67-reactivity, and flow cytometry.
    Tsurusawa M; Aoyama M; Saeki K; Fujimoto T
    Leukemia; 1995 Nov; 9(11):1921-5. PubMed ID: 7475284
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of rGM-CSF on leukemia cell proliferation and on the incorporation of cytosine arabinoside into DNA.
    Gao XZ; Yin MY; Wang ZQ; Raza A; Preisler HD
    Cell Biochem Funct; 1991 Jul; 9(3):155-61. PubMed ID: 1752023
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug effect in acute leukemia.
    Lampkin BC; Nagao T; Mauer AM
    J Clin Invest; 1969 Jun; 48(6):1124-30. PubMed ID: 5253748
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thymidine as a kinetic and biochemical modulator of 1-beta-D-arabinofuranosylcytosine in human acute nonlymphocytic leukemia.
    Blumenreich MS; Chou TC; Andreeff M; Vale K; Clarkson BD; Young CW
    Cancer Res; 1984 Feb; 44(2):825-30. PubMed ID: 6692380
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of tetrahydrouridine on the uptake and metabolism of 1-beta-D-arabinofuranosylcytosine in human normal and leukemic cells.
    Ho DH; Carter CJ; Brown NS; Hester J; McCredie K; Benjamin RS; Freireich EJ; Bodey GP
    Cancer Res; 1980 Jul; 40(7):2444-6. PubMed ID: 6248205
    [No Abstract]   [Full Text] [Related]  

  • 37. Pharmacokinetic parameters of 1-beta-D-arabinofuranosylcytosine (ara-C) and their relationship to intracellular metabolism of ara-C, toxicity, and response of patients with acute nonlymphocytic leukemia treated with conventional and high-dose ara-C.
    Rustum YM; Riva C; Preisler HD
    Semin Oncol; 1987 Jun; 14(2 Suppl 1):141-8. PubMed ID: 3589689
    [No Abstract]   [Full Text] [Related]  

  • 38. Cell kinetics as related to treatment of patients with acute nonlymphoid leukemia.
    Lampkin BC
    Am J Pediatr Hematol Oncol; 1985; 7(4):358-72. PubMed ID: 2417503
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Possible significance of nonproliferating leukemic cells.
    Mauer AM; Saunders EF; Lampkin C
    Natl Cancer Inst Monogr; 1969 May; 30():63-79. PubMed ID: 5351830
    [No Abstract]   [Full Text] [Related]  

  • 40. An in vitro model to predict clinical response in adult acute myelogenous leukemia.
    Karp JE; Donehower RC; Burke PJ
    Semin Oncol; 1987 Jun; 14(2 Suppl 1):172-81. PubMed ID: 3473676
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.